Editor’s Note: This article originally appeared on Abbott’s website. ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today the launch of its Afinion™ 2 analyzer in the U.S.
AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. This system delivers accurate hemoglobin A1c (HbA1c) results in ...
ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its Afinion™ HbA1c Dx assay is now available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 ...
Abbott announced that its Afinion™ HbA1c Dx assay is now available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. The product is the first and only rapid point-of-care test ...
The US Food and Drug Administration (FDA) has approved the Afinion HbA1c Dx assay (Abbott), the first rapid point-of-care test to diagnose diabetes and assess a patient's risk of developing the ...
ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 ...
Abbott announced that its Afinion HbA1c Dx assay is now available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. The Afinion HbA1c Dx assay is the first and only rapid point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results